Records containing: Hydatidiform Mole
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2026-03-16Study of Different Therapeutic Strategies in Hydatidiform Mole With Lung Nodule,A Prospective Multicentre Randomized Controlled Trial
-
CLINICAL_TRIALS study record update · 2025-10-02Application and Promotion of the Whole-process Management and Precision Diagnosis and Treatment System for Hydatidiform Mole: a Multi-center Cohort Study in China (CN-HM-01)
-
CLINICAL_TRIALS study record update · 2022-12-08A Multi-center Cohort Study of Hydatidiform Mole
-
CLINICAL_TRIALS study record update · 2020-04-17The Efficacy of Methotrexate for the Prevention of Postmolar Gestational Trophoblastic Disease Among Patients With High-Risk Hydatidiform Mole
-
CLINICAL_TRIALS study record update · 2019-08-13A Phase III Randomized Trial of Pulse Actinomycin-D Versus Multi-day Methotrexate for the Treatment of Low-Risk Gestational Trophoblastic Neoplasia
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2018-05-15A Randomized Phase III Trial of Weekly Parenteral Methotrexate Versus "Pulsed" Dactinomycin as Primary Management for Low Risk Gestational Trophoblastic Neoplasia
-
CLINICAL_TRIALS study record update · 2016-09-08The French National Reference Centre of Gestational Trophoblastic Disease
-
CLINICAL_TRIALS study record update · 2016-03-23A Comparison of Single Versus Double Evacuation for Treatment of Hydatidiform
-
CLINICAL_TRIALS study record update · 2007-08-09A Phase II Trial of Pemetrexed (Alimta) in the Treatment of Recurrent or Persistent Low Risk Gestational Trophoblastic Tumor